AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
NEW YORK, Dec. 01, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities between May 12, 2014 and November 20, 2015.
Click here to learn about the case: http://docs.wongesq.com/OSIR-Info-Request-Form-1014. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/OSIR-Info-Request-Form-1014.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
